A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration

Psychopharmacology

Volumn 175, Issue 2, 2004, Pages 148-153

  Talvik, Mirjam ^a   Nordström, Anna Lena ^a   Larsen, Niels Erik ^b   Jucaite, Aurelija ^a   Červenka, Simon ^a   Halldin, Christer ^a   Farde, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antipsychotics; D2 receptor; Dopamine; EPS; Occupancy; PANSS; Schizophrenia; Serum concentration; Striatum; Therapeutic window; Threshold

Indexed keywords

CARBON 11; DOPAMINE 2 RECEPTOR; PERPHENAZINE; PERPHENAZINE DECANOATE; RACLOPRIDE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; STEADY STATE; VALIDATION PROCESS;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERPHENAZINE; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE D2; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA;

EID: 4544349440     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-1802-1     Document Type: Article

References (65)

1. 11C-raclopride. Arch Neurol 50:474-480
2. Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45:79-91
3. Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676
4. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc'h C, Maziere B (1989) Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology 99:463-472
5. Bergström M, Boëthius J, Eriksson L, Greitz T, Ribbe T, Widén L (1981) Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. J Comput Assist Tomogr 5:136-141
6. Beyea SC, Nicoll LH (1995) Administration of medications via the intramuscular route: an integrative review of the literature and research-based protocol for the procedure. Appl Nurs Res 8:23-33
7. Cambon H, Baron JC, Boulenger JP, Loc'h C, Zarifian E, Maziere B (1987) In vivo assay for neuroleptic receptor binding in the striatum. Br J Psychiatry 151:824-830
8. Carlsson A (1978) Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 135:164-173
9. Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99:S47-53
10. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483
11. Dahl SG (1986) Plasma level monitoring of antipsychotic drugs. Clinical utility. Clin Pharmacokinet 11:36-61
12. 11]raclopride. Psychopharmacology 107:23-29
13. Farde L, Nordström A (1992) PET analysis indicates atypical central dopamine receptor occupancy in clozapine treated patients. Br J Psychiatry 160 (suppl 17):30-33
14. 2 dopamine receptor binding in the living human brain by PET. Science 231:258-261
15. 2-dopamine receptors by PET. Psychopharmacology 94:471-478
16. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71-76
17. 2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 9:696-708
18. Farde L, Wiesel FA, Nilsson L, Sedvall G (1989b) The potential of positron-emission tomography for pharmacokinetic and pharmacodynamic studies of neuroleptics. Psychopharmacol Ser 7:32-39
19. 2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99:S28-S31
20. 2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine - relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
21. Garver DL (1989) Neuroleptic drug levels and antipsychotic effects: a difficult correlation; potential advantage of free (or derivative) versus total plasma levels. J Clin Psychopharmacol 9:277-281
22. 2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology 135:119-126
23. Gefvert O, Lundberg T, Wieselgren JM, Bergstrom M, Langstrom B, Wiesel F, Lindstrom L (2001) D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 11:105-110
24. Guy W (1976) Clinical Global Impressions ECDEU Assessment Manual for Psychopharmacology. ECDEU - National Institute of Health, pp 218-222
25. 2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 11:245-256
26. Hansen LB, Larsen NE (1977) Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology 53:127-130
27. Hansen LB, Elley J, Christensen TR, Larsen NE, Naestoft J, Hvidberg EF (1979) Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs. Br J Clin Pharmacol 7:75-80
28. Hansen LB, Larsen NE, Gulmann N (1982) Dose-response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology 78:112-115
29. Kane JM, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789-796
30. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 153:948-950
31. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286-293
32. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000a) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520
33. 2 receptor occupancy. Arch Gen Psychiatry 57:553-559
34. 1-dopamine receptor occupancy and pharmacodynamics in man. Psychopharmacology 119:1-8
35. Kay SR, Fiszbein A, Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276
36. Knudsen P, Hansen L, Auken G, Waehrens J, Højholdt K, Larsen N-E (1985a) Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients. Acta Psychiatr Scand Suppl 72:15-28
37. Knudsen P, Hansen L, Auken G, Warens J, Hojholdt K, Larsen N-E (1985b) Efficacy and side effects in a 6 week double-blind comparative study of 50 drug monitored psychotic patients. Acta Psychiatr Scand 1985:15-28
38. Knudsen P, Hansen L, Højholdt K, Larsen N-E (1985c) Long-term depot neuroleptic treatment with perphenazine decanoate 1. Acta Psychiatr Scand Suppl 72:29-40
39. Knudsen P, Hansen L, Højholdt K, Larsen N-E (1985d) Long-term depot neuroleptic treatment with perphenazine decanoate 2. Acta Psychiatr Scand Suppl 72:41-50
40. Koch-Weser J, Sellers EM (1976a) Binding of drugs to serum albumin (first of two parts). N Engl J Med 294:311-316
41. Koch-Weser J, Sellers EM (1976b) Drug therapy. Binding of drugs to serum albumin (second of two parts). N Engl J Med 294:526-531
42. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158
43. Larsen NE, Hansen LB (1989) Prediction of the optimal perphenazine decanoate dose based on blood samples drawn within the first three weeks. Ther Drug Monit 11:642-646
44. Larsson M, Forsman A (1983) A high-performance liquid Chromatographic method for the assay of perphenazine and its dealkylated metabolite in serum after therapeutic doses. Ther Drug Monit 5:225-228
45. 11C]raclopride binding in healthy young adults and schizophrenic patients-reliability and age effects. Hum Psychopharmacol 7:157-165
46. 2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 110:365-367
47. 2-dopamine receptor occupancy in relation to antipsychotic drug effects - a double blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235
48. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152:1444-1449
49. 2 receptor occupancy. A PET study in haloperidol-treated patients. Psychiatry Res 67:163-171
50. Nyberg S, Dencker SJ, Malm U, Dahl ML, Svenson JO, Halldin C, Naskashima Y, Farde L (1998) D(2)- and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated patients. Int J Neuropsychopharmcol 1:95-101
51. Peroutka SJ, Snyder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137:1518-1522
52. 11C] raclopride. J Cereb Blood Flow Metab 13:310-314
53. Ross EG (1985) Pharmacodynamics: mechanisms of drug action and the relationship between drug concentration and effect. In: Gilman AG, Rall L, Murad F (eds) The pharmacological basis of therapeutics. Macmillan, New York, pp 35-48
54. Rowland MT (1995) Clinical pharmacokinetics concepts and applications, 3rd edn. Williams and Wilkins, Baltimore
55. Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-719
56. Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11-19
57. I8F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients. Biol Psychiatry 23:653-663
58. Talbot PS, Lamelle M (2002) The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 12:503-511
59. 11C]FLB 457. Am J Psychiatry 158:926-930
60. 123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology 162:42-49
61. van Rossum JM (1966) The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 160:492-494
62. Verbeeck RK, Cardinal JA, Hill AG, Midha KK (1983) Binding of phenothiazine neuroleptics to plasma proteins. Biochem Pharmacol 32:2565-2570
63. Wienhard K, Dahlbom M, Eriksson L, Michel C, Bruckbauer T, Pietrzyk U, Heiss W (1994) The ECAT EXACT HR: performance of a new high resolution positron scanner. J Comput Assist Tomogr 18:110-118
64. 11C]raclopride. Neuropsychopharmacology 27:248-259
65. Zia H, Price JC (1975) Binding study of sulfonylureas and phenothiazines to bovine serum albumin using difference spectrophotometry. J Pharm Sci 64:1177-1181